Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
55 hedge funds and large institutions have $40.4M invested in Viracta Therapeutics, Inc. Common Stock in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 8 closing their positions.
274% more call options, than puts
Call options by funds: $654K | Put options by funds: $175K
46% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 13
29% more capital invested
Capital invested by funds: $31.3M → $40.4M (+$9.16M)
7% less funds holding
Funds holding: 59 → 55 (-4)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$4.45M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$2.03M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$1.87M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$1.11M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$775K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.49M |
| 2 |
PA
Perceptive Advisors
New York
|
-$567K |
| 3 |
QSS
Quantitative Systematic Strategies
Ponte Vedra Beach,
Florida
|
-$305K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$273K |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$237K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FCM
51
Farallon Capital Management
San Francisco,
California
| – | -$2.49M | -14,645 | Closed |
|
|
PA
52
Perceptive Advisors
New York
| – | -$567K | -3,333 | Closed |
|
|
QSS
53
Quantitative Systematic Strategies
Ponte Vedra Beach,
Florida
| – | -$305K | -1,588 | Closed |
|
|
GTC
54
Ghost Tree Capital
New York
| – | -$237K | -1,395 | Closed |
|
|
ECM
55
Endurant Capital Management
San Mateo,
California
| – | -$156K | -919 | Closed |
|
56
Millennium Management
New York
| – | -$96K | -564 | Closed |
|
|
MA
57
MUFG Americas
New York
| – | -$3K | -17 | Closed |
|
58
Walleye Trading
New York
| – | -$748 | -4 | -67% |
|
|
CI
59
Cowen Inc
New York
| – | +$66.8K | +357 | New |
|
VIRX Hedge Fund Activity: Q4 2015 in Review
55 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q4 2015, worth a combined $40.4M — up 29% from $31.3M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of VIRX and 4 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 19 added.
The largest buyer was Great Point Partners, adding an estimated $4.45M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $2.49M sold.
- 55 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q4 2015, down from 59 in Q3 2015.
- Funds reported $40.4M of Viracta Therapeutics, Inc. Common Stock stock for Q4 2015, up 29% quarter-over-quarter.
- 4 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q4 2015 and 8 closed out, a net change of -4 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q4 2015 was Great Point Partners, an estimated $4.45M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q4 2015 was Farallon Capital Management, an estimated $2.49M sold.
Based on aggregated 13F filings for Q4 2015.